Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Fraunhofer ITEM: Successful testing of new drug for allergic asthma

18.05.2015

A novel therapeutic principle is aimed at controlling the airway inflammation in allergic asthma, to mitigate the course of the disease. With its comprehensive expertise, Fraunhofer ITEM successfully performed toxicology testing of the novel DNAzyme-based drug developed by sterna biologicals GmbH & Co. KG and also part of the clinical trials. The results of the proof-of-concept study in man have now been published in the renowned “New England Journal of Medicine”.

Asthma is a highly prevalent airway disease, affecting an estimated 300 million people worldwide. Asthmatics suffer not only from the disease itself, but also from its wide-ranging consequences. The therapeutic options for severe asthma to date are little satisfactory and require a new therapeutic principle. This is what sterna biologicals has developed with the new drug “SB010”.


Body plethysmography at the Fraunhofer ITEM: Inhaled treatment with the new drug “SB010”, developed by sterna biologicals, significantly improved lung function in patients with asthma.

It is based on inhibiting the transcription factor GATA-3 by a so-called DNAzyme – a synthetic DNA molecule with enzymatic action for inhaled administration. It binds to the transcription factor that triggers the inflammatory response and thus the typical asthma symptoms, inactivating it by enzymatic cleavage.

The Fraunhofer ITEM has accompanied development of this first-in-class antagonist with its expertise, from scientific advice and the required toxicity tests (in cooperation with Nycomed GmbH) to clinical trials of phases Ib and IIa. The latter, i.e. the proof-of-concept study, was conducted as a multi-center study in seven German centers under the scientific direction of Professor Norbert Krug, Fraunhofer ITEM Medical Director.

In the randomized, double-blind, parallel-group, multi-center trial, efficacy of the new therapeutic agent was tested. Treatment with “SB010” over 28 days significantly improved lung function after specific allergen challenge as compared to placebo. “SB010” furthermore proved to be safe and well tolerated. The results of this study were presented during this year’s International Conference of the American Thoracic Society in Denver, USA.

“Recent research indicates that approximately 50 percent of all asthmatics suffer from allergic asthma. This type of asthma is Th2-driven across all levels of disease severity. Therefore, developing novel therapeutics specifically for this group of patients holds great promise, in particular of drugs for inhaled delivery. Further clinical trials with ‘SB010’ in a larger cohort of asthmatics are thus warranted,” explains Krug.

Contact
Fraunhofer ITEM
Prof. Dr. Norbert Krug; +49 511 5350-8100
norbert.krug@item.fraunhofer.de

Press contact
Fraunhofer ITEM
Dr. Cathrin Nastevska; +49 511 5350-225
cathrin.nastevska@item.fraunhofer.de

The text of this press release including an image for download can be found on our homepage at http://www.item.fraunhofer.de/en/press-media/latest-news/pm_sternaSB010.html

Weitere Informationen:

http://www.item.fraunhofer.de/en/press-media/latest-news/pm_sternaSB010.html

Kommunikation | Fraunhofer-Gesellschaft

More articles from Life Sciences:

nachricht Lethal combination: Drug cocktail turns off the juice to cancer cells
12.12.2018 | Universität Basel

nachricht Smelling the forest – not the trees
12.12.2018 | Universität Konstanz

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Lethal combination: Drug cocktail turns off the juice to cancer cells

A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth – this was discovered by researchers from the University of Basel’s Biozentrum two years ago. In a follow-up study, recently published in “Cell Reports”, the scientists report that this drug cocktail induces cancer cell death by switching off their energy supply.

The widely used anti-diabetes drug metformin not only reduces blood sugar but also has an anti-cancer effect. However, the metformin dose commonly used in the...

Im Focus: New Foldable Drone Flies through Narrow Holes in Rescue Missions

A research team from the University of Zurich has developed a new drone that can retract its propeller arms in flight and make itself small to fit through narrow gaps and holes. This is particularly useful when searching for victims of natural disasters.

Inspecting a damaged building after an earthquake or during a fire is exactly the kind of job that human rescuers would like drones to do for them. A flying...

Im Focus: Topological material switched off and on for the first time

Key advance for future topological transistors

Over the last decade, there has been much excitement about the discovery, recognised by the Nobel Prize in Physics only two years ago, that there are two types...

Im Focus: Researchers develop method to transfer entire 2D circuits to any smooth surface

What if a sensor sensing a thing could be part of the thing itself? Rice University engineers believe they have a two-dimensional solution to do just that.

Rice engineers led by materials scientists Pulickel Ajayan and Jun Lou have developed a method to make atom-flat sensors that seamlessly integrate with devices...

Im Focus: Three components on one chip

Scientists at the University of Stuttgart and the Karlsruhe Institute of Technology (KIT) succeed in important further development on the way to quantum Computers.

Quantum computers one day should be able to solve certain computing problems much faster than a classical computer. One of the most promising approaches is...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

ICTM Conference 2019: Digitization emerges as an engineering trend for turbomachinery construction

12.12.2018 | Event News

New Plastics Economy Investor Forum - Meeting Point for Innovations

10.12.2018 | Event News

EGU 2019 meeting: Media registration now open

06.12.2018 | Event News

 
Latest News

New discoveries predict ability to forecast dementia from single molecule

12.12.2018 | Health and Medicine

CCNY-Yale researchers make shape shifting cell breakthrough

12.12.2018 | Physics and Astronomy

Pain: Perception and motor impulses arise in the brain independently of one another

12.12.2018 | Health and Medicine

VideoLinks
Science & Research
Overview of more VideoLinks >>>